A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hemophilia B

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States

  • David Geffen School of Medicine at UCLA, Los Angeles, California, United States

  • Children's Hospital Los Angeles, Los Angeles, California, United States

  • University of California Davis, Sacramento, California, United States

  • University California San Francisco, San Francisco, California, United States

  • University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States

  • Yale HTC, New Haven, Connecticut, United States

  • University of Florida, Gainesville, Florida, United States

  • Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States

  • Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders, New Orleans, Louisiana, United States

  • University of Michigan, Ann Arbor, Michigan, United States

  • Nationwide Children's Hospital, Columbus, Ohio, United States

  • Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States

  • Vanderbilt University Medical Center, Nashville, Tennessee, United States

  • Royal Prince Alfred Hospital, Haemophilia Treatment Centre, Camperdown, New South Wales, Australia

  • Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

  • Royal Adelaide Hospital, Adelaide, South Australia, Australia

  • University of Alberta Hospital, Edmonton, Alberta, Canada

  • McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada

  • McGill University Health Center (MUHC), Montreal, Quebec, Canada

  • Hospices Civils de Lyon, Bron, Lyon, France

  • Hemostase Clinique, Institut Coeur Poumon, Lille, Nord, France

  • Hopital Necker, Paris, Île-de-France Region, France

  • University Hospital Frankfurt, Frankfurt am Main, Hesse, Germany

  • University Hospital Hamburg Eppendorf, Hamburg, Germany

  • Careggi University Hospital, Florence, Firenze, Italy

  • Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy

  • Irccs Humanitas Research Hospital, Rozzano, Lombardy, Italy

  • Ospedale san Bortolo, Vicenza, Italy

  • Hospital Universitario Virgen del Rocio, Seville, Andalusia, Spain

  • Complejo Hospitalario Universitario de A Coruña (Edificio Teresa Herrera-Materno Infantil), A Coruña, Galicia, Spain

  • Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar, Murcia, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Principality of Asturias, Spain

  • Hospital Universitario Vall d'Hebron, Barcelona, Spain

  • Hospital Universitario La Paz, Madrid, Spain

  • Haemostasis and Thrombosis Unit, Hospital La Fe, Valencia, Spain

  • Hospital Universitario Miguel Servet, Zaragoza, Spain

  • Glasgow Royal Infirmary - Clinical Research Facility, Glasgow, Scotland, United Kingdom

  • Queen Elizabeth Hospital Birmingham, Birmingham, West Midlands, United Kingdom

  • Addenbrooke's Hospital, Cambridge University Hospitals NHS FT, Cambridge, United Kingdom

  • Pathology and Pharmacy Building, The Royal London Hospital, London, United Kingdom

  • Royal Free London NHS Foundation Trust, London, United Kingdom

  • St. Thomas' Hospital, London, United Kingdom

  • Hammersmith Hospital Comprehensive Care Centre, London, United Kingdom

Study leads
  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals